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HIV-2 infects resting CD4+ T cells but not
monocyte-derived dendritic cells
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Abstract
Background: Human Immunodeficiency Virus-type 2 (HIV-2) encodes Vpx that degrades SAMHD1, a cellular restriction
factor active in non-dividing cells. HIV-2 replicates in lymphocytes but the susceptibility of monocyte-derived dendritic
cells (MDDCs) to in vitro infection remains partly characterized.
Results: Here, we investigated HIV-2 replication in primary CD4+ T lymphocytes, both activated and non-activated, as
well as in MDDCs. We focused on the requirement of Vpx for productive HIV-2 infection, using the reference HIV-2 ROD
strain, the proviral clone GL-AN, as well as two primary HIV-2 isolates. All HIV-2 strains tested replicated in activated
CD4+ T cells. Unstimulated CD4+ T cells were not productively infected by HIV-2, but viral replication was triggered
upon lymphocyte activation in a Vpx-dependent manner. In contrast, MDDCs were poorly infected when exposed to
HIV-2. HIV-2 particles did not potently fuse with MDDCs and did not lead to efficient viral DNA synthesis, even in the
presence of Vpx. Moreover, the HIV-2 strains tested were not efficiently sensed by MDDCs, as evidenced by a lack of
MxA induction upon viral exposure. Virion pseudotyping with VSV-G rescued fusion, productive infection and HIV-2
sensing by MDDCs.
Conclusion: Vpx allows the non-productive infection of resting CD4+ T cells, but does not confer HIV-2 with the ability
to efficiently infect MDDCs. In these cells, an entry defect prevents viral fusion and reverse transcription independently
of SAMHD1. We propose that HIV-2, like HIV-1, does not productively infect MDDCs, possibly to avoid triggering an
immune response mediated by these cells.
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Background
HIV-1 and HIV-2 share many similarities in their genetic
organization, modes of replication and potential inter-
action with their hosts [1]. However, major differences
exist regarding the clinical consequences of infection. In
the absence of antiretroviral treatment, progression to
immunodeficiency is more rare and occurs more slowly
with HIV-2 than with HIV-1 [1,2]. About 10-30% of
HIV-2-infected patients are long-term non-progessors or
viral controllers [3-5]. Viral RNA levels in HIV-2 infec-
tion are about 30 times lower than in HIV-1 infection,
and viral DNA levels are also reduced [1,2,6-9]. However,
as for HIV-1, disease progression in HIV-2-infected
individuals has been associated with increased chronic im-
mune activation, CD4+ T cell depletion and alterations in
circulating monocytes and myeloid DCs [1,2,10-13].
Why HIV-2 is less pathogenic than HIV-1, and why
HIV-2 provides partial cross-protection against HIV-1
disease progression in dually infected individuals, re-
mains partly understood [1,4,14,15]. It has been pro-
posed that HIV-2 replication may be more efficiently
controlled by the immune response. For instance, most
of HIV-2-infected individuals produce neutralizing anti-
bodies [2,16]. HIV-2 is more sensitive to neutralization
than HIV-1, likely because HIV-2 Env proteins expose
multiple cross-reactive epitopes and have fewer glycosyla-
tion sites in the V3 loop than HIV-1 [17-19]. In addition
to a strong humoral response, HIV-2-infected donors have
well-preserved and polyfunctional HIV-specific CD4+ and
CD8+ T cell responses that are associated with delayed
disease progression [20-22]. The innate immune response
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may also be very active against HIV-2. It has been re-
ported that in vitro, HIV-1 is more resistant to type-I IFN
than HIV-2 and SIVmac [23]. This suggests that some cel-
lular restriction factors, induced by type-I IFN, may be
particularly active against HIV-2. For example, HIV-2 is
more sensitive to restriction by Trim5α than is HIV-1
[24]. There are strain-specific variations in HIV-2 sensitiv-
ity to Trim5α, depending on motifs within the capsid [25].
Lv2 is another example of an unidentified factor that re-
stricts infection of some HIV-2 viruses, but not HIV-1, fol-
lowing virus entry [26,27]. The block manifests after
reverse transcription but prior to nuclear entry, and sensi-
tivity to restriction maps to the HIV-2 envelope and capsid
genes [26,27]. Tetherin, a cellular protein blocking viral re-
lease, is also differently counteracted by HIV-1 and HIV-2.
In HIV-1, the anti-tetherin activity is conferred by Vpu,
whereas in HIV-2, the intracytoplasmic portion of Env
mediates this effect [28,29]. Another protein, the recently
identified RNA-associated early-stage anti-viral factor
(REAF), inhibits both HIV-1 and HIV-2 just after cell
entry [30].
The restriction factor SAMHD1 blocks HIV replica-
tion by degrading intracellular dNTPs and HIV-1 RNA
[31-37]. SAMHD1 inhibits reverse transcription in non-
diving cells, such as monocytes, macrophages, dendritic
cells and non-activated CD4+ lymphocytes [31-36]. In
dividing cells such as activated CD4+ T cells, SAMHD1
is phosphorylated and does not restrict HIV-1 [38-40].
HIV-2 and some SIV strains encode the accessory pro-
tein Vpx, which degrades SAMHD1 and allows escape
from this restriction, whereas HIV-1 lacks a Vpx-like
activity. The anti-SAMHD1 activity is conserved in Vpx
alleles isolated from viremic or aviremic HIV-2-infected
individuals [41]. It has been proposed that HIV-2,
through the SAMHD1-degrading action of Vpx, may
trigger a more efficient immune response by product-
ively infecting dendritic cells (DCs) [42]. HIV-1, in spar-
ing SAMHD1, may avoid productive infection of DCs
and thus limit the resulting protective type-I IFN re-
sponse mounted by these cells [35,43-45]. In addition to
degrading SAMHD1, Vpx may also inhibit the function
of IRF-5 [46]. Of note, HIV-1 and HIV-2 differentially
interact with other target cells. The kinetics of HIV-1
and HIV-2 replication are different in human primary
macrophage cultures [47]. Exposure of plasmacytoid
DCs (pDCs) to HIV-1 and HIV-2 differentially mature
the cells into IFN-producing cells or Antigen Presenting
Cells [48].
The exact role of Vpx during HIV-2 replication is not
fully understood. A comparison between wild-type and
Vpx-deleted HIV-2 demonstrated that Vpx is not neces-
sary for viral replication in activated CD4+ T cells and in
T cell lines [49-51]. In contrast, HIV-2 infection is
poorly supported in resting (non-stimulated) CD4+ T
cells. Even in the presence of Vpx, less than 2% of non-
stimulated CD4+ T cells are productively infected [36].
Vpx is also required for the productive infection of mac-
rophages by HIV-2 virions pseudotyped with VSV-G
[41]. There is controversy regarding the sensitivity of
DCs to HIV-2 infection. It has been reported that HIV-2
efficiently replicated in monocyte-derived DCs (MDDCs),
using the laboratory-adapted HIV-2 ROD strain, pseudo-
typed with VSV-G [42,44]. This efficient replication was
associated with an immune detection of incoming viral
cDNA by the innate sensor cGAS [42] and with DC
maturation. Others reported that neither CCR5-tropic pri-
mary HIV-2 isolates nor a CXCR4-tropic laboratory-
adapted viral strain could efficiently infect primary myeloid
DCs or pDCs, though these viruses could infect primary
CD4+ T cells [52]. Moreover, HIV-2 exposure did not pro-
mote full maturation of DCs [41,52]. These different re-
sults may be due to different experimental systems, DC
subsets, or viral strains, and/or to the use of VSV-G-
pseudotyped HIV-2 in some studies.
In this study, we explored some virological and im-
munological aspects of the interaction of HIV-2 with
CD4+ T cells and MDDCs. As previously described,
HIV-2 spread in primary activated lymphocytes. In rest-
ing T cells, productive HIV-2 infection was not detected,
but subsequent activation of HIV-2-exposed lympho-
cytes led to viral replication in a Vpx-dependent manner.
In contrast, monocyte-derived DCs (MDDCs) were
poorly sensitive to HIV-2 infection, even in the presence
of Vpx, and the HIV-2 isolates tested did not trigger a
strong type-I IFN response in MDDCs. Therefore, our
data do not support the hypothesis that Vpx-mediated
SAMHD1 degradation allows HIV-2 productive infec-
tion of MDDCs, and thus a potential difference in the
ability of HIV-1 and HIV-2 to infect this cell type may
not underlie differences in disease pathogenesis.
Results
HIV-2 primary strains replicate in activated CD4+ T cells
and infect resting CD4+ T cells
We first verified that the different HIV-2 strains used in
this study replicated in primary CD4+ T cells. We puri-
fied CD4+ T cells from PBMCs from healthy donors, ex-
posed them to phytohemaglutinin (PHA) to induce
activation, and incubated them with viral particles nor-
malized for p27 antigen levels. We used two primary
viral biological isolates, a group B dual-tropic strain
(ROK) and a group A X4-tropic strain (TOE), both iso-
lated from aviremic patients (see materials and methods
for a description of the viruses), and as a reference the
group A dual-tropic prototype ROD isolate. Viral repli-
cation was assessed by flow cytometry, after intracellular
staining with the anti-HIV-1 Gag monoclonal antibody
KC57, which also recognizes HIV-2 Gag [52]. The HIV-2
Chauveau et al. Retrovirology  (2015) 12:2 Page 2 of 13
isolates replicated in CD4+ T cells, with 15-30% of Gag +
cells at day 5 post-infection (p.i.) (Figure 1a). HIV-1
(NL4.3 strain) efficiently replicated in the same cells
(Figure 1a). The appearance of HIV-2 Gag + cells was as-
sociated with viral release in the supernatants, reaching
50–100 ng mL−1 of Gag p27 at day 5 p.i. (Figure 1a). HIV-2
encodes Vpx, which degrades the restriction factor
SAMHD1 [31-36]. As expected, we observed a strong de-
crease of SAMHD1 in HIV-2-infected (Gag+) cells
whereas HIV-1 replicated without degrading SAMHD1
(Figure 1b). With HIV-2, the SAMHD1-negative and
Gag-negative population (Figure 1b) may represent cells
Figure 1 HIV-2 replication in activated and in unstimulated CD4+ T cells. (a) Replication of different HIV-2 isolates in activated CD4+ T cells.
Primary activated CD4+ T cells were infected with the laboratory-adapted HIV-2 strain ROD or with TOE and ROK, two HIV-2 isolated from infected
patients (viral inoculum was 30 ng p27 mL−1). The HIV-1 NL strain (30 ng p24 mL−1) was used as a control. Viral replication was followed by
intracellular Gag staining and quantification of Gag release in the supernatants. NI: Non infected. Results are Mean ± SEM of 6 independent donors.
(b) SAMHD1 down-regulation. At day 5 post-infection (p.i.), Gag and SAMHD1 levels were analyzed by flow cytometry. One representative donor, out
of 6, is shown. (c) Infection of resting, unstimulated CD4+ T cells with different HIV-2 strains. Unstimulated CD4+ T cells were exposed to HIV-2 ROD,
ROK (30 ng p27 mL−1) or TOE (15 ng p27 mL−1) for 4 h. One day post-infection, cells were activated or not with PHA/IL-2. Gag and SAMHD1 levels were
measured over time by flow-cytometry. Data are Mean ± SEM of 5 independent donors.
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in which incoming Vpx degraded SAMHD1 before, or in
the absence of, productive infection.
We then asked whether HIV-2 infects resting CD4+
lymphocytes. We purified unstimulated CD4+ T cells
from PBMCs, and verified that >95% did not express the
activation and proliferation markers CD69 and Ki67
(Additional file 1: Figure S1). These cells were exposed
to the HIV-2 isolates ROD, ROK or TOE as well as to
HIV-1 (NL4.3) and were cultivated with minimal doses
of IL-2 to prevent cell death. As expected [36], no viral
replication was detected in these cells up to 9 days post
viral challenge (Figure 1c). Of note, the slight down-
regulation of SAMHD1 observed in non-activated
CD4 + T cells (in about 10% of the cells) over time
(mostly after 7–9 days of culture) may represent dead
or dying cells (Figure 1c). However, PHA activation,
one day following viral exposure, led to significant
HIV-1 and HIV-2 replication. In the case of HIV-2,
concomitant and strong SAMHD1 down-regulation
was observed in activated cells (Figure 1c). Similar re-
sults were obtained when CD4+ T cells were activated
4 days after viral exposure (not shown).
Role of HIV-2 Vpx in primary CD4+ T cells
To assess the role of Vpx in infection of activated or un-
stimulated CD4+ T cells, we followed replication of an
HIV-2 molecular clone, the GL-AN provirus, expressing
or not the viral accessory protein (GL-AN WT and ∆Vpx,
respectively) [50]. GL-AN is a chimerical strain, originat-
ing from a virus isolated in a Ghanaian patient, and con-
taining a large part of the HIV-2 ROD env sequence [50].
GL-AN replicated in activated primary CD4+ T cells, and
the absence of Vpx was associated with a slight but non-
significant decrease of viral growth (Figure 2a). GL-AN
WT, and not ∆Vpx down-regulated SAMHD1 in infected
cells (Figure 2a). With GL-ANWT, the extent of SAMHD1
down-regulation was less marked than with ROD, ROK
and TOE (Figure 1b). This suggests that, as previously re-
ported [41], Vpx from different viral isolates down-
regulate SAMHD1 with various efficiencies. However, with
GL-AN WT, the majority of Gag + cells were SAMHD1-
negative, whereas ∆Vpx replicated in SAMHD1-positive
cells (Figure 2a). This is not surprising since SAMHD1 is
phosphorylated in cycling cells, and this phosphorylation
inactivates the enzyme [38-40].
In resting CD4+ T cells, as observed with the other
HIV-2 strains, the GL-AN viruses did not lead to pro-
ductive infection. However, GL-AN WT, but not GL-AN
∆Vpx, replicated in CD4+ T cells stimulated one day
(Figure 2b) or four days (not shown) following viral
challenge. This replication was associated with a down-
regulation of SAMHD1.
Altogether, these results suggest that upon HIV-2 ex-
posure, unstimulated lymphocytes harbor virus but do
not produce viral antigens. This may be due to pre-
integration defects and/or a HIV LTR transcription
block associated with their quiescent status [31]. More-
over, this non-productive infection requires Vpx, and
leads to viral outgrowth after lymphocyte stimulation.
Monocyte-derived dendritic cells are poorly sensitive to
HIV-2
We then asked whether MDDCs may be infected by
HIV-2 and evaluated the consequences of viral exposure
on expression of the interferon-stimulated gene MxA
[53]. Cells were exposed to the HIV-2 strains ROD,
TOE, ROK, and to GL-AN WT or ∆Vpx. The extent of
infection was measured by double staining for Gag and
SAMHD1 after 3 days and analyzing by flow cytometry
(Figure 3a). One representative experiment is shown in
Figure 3a, and the values obtained from up to 6 inde-
pendent donors are shown in Figure 3b,c. At the high
dose of virus used (150 ng p27 mL−1), very few Gag +
cells were detected (<3% of MDDCs were Gag + at 72 h,
Figure 3b) and this percentage did not further increase
at 96 h p.i. (Additional file 1: Figure S1c). Augmenting
the viral inoculum to 500 ng p27 mL−1 did not improve
the efficiency of infection, nor did pre-treatment of the
cells with SIV-derived virus like particles carrying Vpx
that completely down-regulated SAMHD1 (not shown).
SAMHD1 was partly down-regulated in cells exposed to
ROD and, to even a lesser extent, to ROK (which are
dual-tropic viruses), but this was not observed for the
X4-tropic TOE strain (Figure 3b). GL-AN WT, and not
∆Vpx, also partly down-regulated SAMHD1 (Figure 3c).
This suggests that incoming Vpx present in the virions
could access the cytoplasm of target cells to a certain ex-
tent. This low efficiency of productive infection with
ROD, TOE, ROK and GL-AN isolates did not lead to
the induction of MxA (Figure 3 b,c).
VSV-G pseudotyping allows productive HIV-2 infection
and viral sensing in MDDCs
The fact that the various HIV-2 strains tested promoted
only a partial down-regulation of SAMHD1 suggested
that viral entry was impaired in MDDCs. We thus exam-
ined the effect of VSV-G pseudotyping on HIV-2 infection
by exposing MDDCs to GL-AN (VSV) WT and GL-AN
(VSV) ∆Vpx virions. One representative experiment is
shown in Figure 3a, and the values obtained with 8 inde-
pendent donors are shown in Figure 3b,c. Depending on
the donor, we observed 10-70% of Gag + cells following
exposure to GL-AN (VSV) WT. The Gag signal corre-
sponded to newly synthesized viral proteins, since it was
no longer detected in the presence of the reverse tran-
scriptase inhibitor AZT (Figure 3d). This efficient infec-
tion was associated with a potent down-regulation of
SAMHD1 in up to 90% of the cells. SAMHD1 remained
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down-regulated in the presence of AZT, indicating that in-
coming Vpx was responsible for this effect. Moreover, GL-
AN (VSV) WT triggered expression of MxA (Figure 3d
and Additional file 1: Figure S1b). AZT inhibited MxA
production, indicating that viral DNA synthesis was re-
quired to mediate sensing of GL-AN (VSV). We then ex-
amined the role of Vpx. GL-AN (VSV) ∆Vpx did not
productively infect MDDCs nor did it down-regulate
SAMHD1 (Figure 3d). Moreover, this virus did not induce
MxA in target cells.
Taken together, these results show that VSV-G pseu-
dotyping allows efficient infection of MDDCs by HIV-
2. This productive infection leads to sensing of the
virus.
Figure 2 Vpx is necessary for HIV-2 infection in unstimulated CD4+ T cells. (a) Replication of HIV-2 GL-AN, expressing or not Vpx, in
activated CD4+ T cells. Primary activated CD4+ T cells were infected with HIV-2 GL-AN WT and GL-AN ∆Vpx (20–30 ng p27 mL−1). Viral replication
was followed as in Figure 1a. Upper panels: Mean ± SD of 6 independent donors. Lower panels: Gag and SAMHD1 expression at day 7 p.i., in one
representative donor. ns: non significant (b) Role of Vpx in HIV-2 infection of resting, unstimulated CD4+ T cells. Unstimulated CD4+ T cells
were exposed to HIV-2 GL-AN WT and GL-AN ∆Vpx (30 and 90 ng p27 mL−1, respectively) as described in Figure 1c. One day post-infection,
the cells were activated with PHA/IL-2. Gag and SAMHD1 levels are shown at different days p.i. Data are Mean ± SEM of 3 independent donors.
*: p-value < 0.05.
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VSV-G pseudotyping increases HIV-2 fusion and reverse
transcription in MDDCs
We characterized the replicative defect of HIV-2 in
MDDCs by comparing the ability of wild-type and VSV-
G-pseudotyped virus to bind cells, undergo fusion and
perform reverse transcription. To measure viral binding
at the cell surface, we incubated MDDCs with increas-
ing doses of GL-AN and GL-AN (VSV) (50 and 150 ng
Figure 3 HIV-2 infection of monocyte-derived dendritic cells (MDDCs). (a) Infection of MDDCs by primary HIV-2. MDDCs were exposed to
HIV-2 ROD, GL-AN (150 ng p27 mL-1) and GL-AN (VSV) (50 ng p27 mL-1). After 3 days, the levels of Gag and SAMHD1 were measured by flow
cytometry. A representative experiment is depicted. (b) Infection with HIV-2 ROD, TOE (150 ng p27 mL-1) and ROK (100 ng p27 mL-1). After 3 days,
the levels of Gag, SAMHD1 and MxA were measured by flow cytometry. Data are Mean of 6 independent donors. The innate response was
analyzed by measuring by flow cytometry the levels of the interferon-stimulated gene MxA. (c) Infection of MDDCs by HIV-2 GL-AN expressing or
not Vpx. MDDCs were exposed to HIV-2 GL-AN WT and GL-AN ∆Vpx (150 ng p27 mL-1) and analyzed as described in (b). (d) Infection of MDDCs
with HIV-2 GL-AN WT or ∆Vpx virions pseudotyped with VSV-G. MDDCs were exposed to HIV-2 GL-AN (VSV) WT and GL-AN (VSV) ΔVpx (50 ng
p27 mL-1) and analyzed as described in (b).
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p27 mL−1) for 2 h at 4°C. After extensive washes, p27
Gag levels were measured in cell lysates by ELISA. The
viruses bound to the cells in a dose dependent manner
(Figure 4a). VSV-G pseudotyping resulted in a slight but
non-significant increase in viral binding (Figure 4a). We
then performed a viral fusion assay to assess the post-
binding step of the viral cycle. HIV-2 Vpr, which is
incorporated into viral particles, was fused with ß-lacta-
mase (Blam-Vpr2) [54,55]. The successful cytoplasmic
access of Blam-Vpr2, as a result of viral fusion, after 2 h
of infection, was monitored by enzymatic cleavage of
CCF2-AM, a fluorogenic substrate of ß-lactamase loaded
in target cells [54,55]. A representative experiment is
shown in Figure 5b. A dose–response analysis of the viral
inoculum (8 to 400 ng p27 mL−1) indicated that wild-type
HIV-2 fusion in MDDCs was low (Figure 4b). In sharp
contrast, a positive fusion signal was detected with GL-
AN (VSV), starting at the lowest viral inoculum tested
(Figure 4b). A side-by-side comparison indicated that fu-
sion of the VSV-G-pseudotyped HIV-2 with MDDCs was
50 times more efficient than that of the wild-type virus.
We then quantified the reverse transcription products at
day 3 post-infection. In line with the results obtained in
the fusion assay, GL-AN did not permit an efficient syn-
thesis of viral DNA, even at a high viral inoculum. In
contrast, infection with VSV-G-pseudotyped HIV-2 was
associated with high levels of viral DNA. This signal cor-
responded to newly synthesized molecules since it was
inhibited by AZT (Figure 4c).
Similar results were obtained when using another HIV-2
strain (ROD-GFP) pseudotyped or not with VSV-G. ROD-
GFP is derived from ROD9 and carries the GFP gene in
place of Nef [36]. We therefore used the GFP signal to
quantify productively infected cells. ROD-GFP did not
lead to productive infection of MDDCs, whereas VSV-G
pseudotyping rescued viral infectivity (Figure 5a). ROD-
GFP bound to MDDCs (Figure 5b), but was unable to fuse
(Figure 5c) and to promote viral DNA synthesis
(Figure 5d).
Altogether, these results indicate that HIV-2 poorly in-
fects MDDCs because of a defect in target cell entry.
This defect is overcome by VSV-G pseudotyping, which
rescues viral infectivity in these cells.
Discussion
We studied here HIV-2 replication in primary CD4+ T
cells and in MDDCs. We used two primary HIV-2
strains (ROK and TOE), as well as the reference isolate
ROD. We focused on the role of Vpx by using the HIV-
2 molecular clones GL-AN and ROD-GFP, expressing or
not this viral protein.
The HIV-2 isolates replicated in activated CD4+ T
cells, as evidenced by the appearance of Gag + cells and
by the release of Gag p27 in the supernatants. At each
time point, the fraction of Gag + cells was lower than with
the HIV-1 strain (NL4.3) tested in parallel. For instance, at
day 4 p.i., about 40% of the cells were Gag + with HIV-1,
whereas the different HIV-2 strains led to 5 to 25% of in-
fected cells. It is however difficult to formally conclude
that HIV-2 spreads less potently than HIV-1 in activated
T cells because only one HIV-1 strain was tested here in
parallel. Of note, the anti-Gag antibody used in this study
(KC57) may recognize HIV-2 antigens less efficiently than
those of HIV-1. However, the use of another anti-HIV-2
Gag-specific mAb (25/26A) did not lead to the detection
of an increased number of infected cells (not shown). Ac-
cordingly, it has been previously reported that in PBMCs
infected in vitro, the total amount of viral DNA is lower
with HIV-2 ROD than with HIV-1 NL4.3 [56]. We further
observed that the mean fluorescence intensity (MFI) of
Gag staining was higher with HIV-1 than with HIV-2. This
may again reflect a different affinity of the antibody, or
may indicate that the number of Gag proteins per infected
cell is relatively low with HIV-2.
We characterized the role of Vpx during HIV-2 repli-
cation in primary CD4+ T cells. As expected [49-51],
both WT and ∆Vpx HIV-2 replicated in PHA-activated
lymphocytes, with replication decreasing slightly in the
absence of Vpx. Interestingly, all HIV-2 isolates led to a
down-regulation of SAMHD1 in infected cells, whereas
HIV-1 replicated without degrading this cellular restric-
tion factor. Overall, Vpx was not necessary for HIV-1 or
HIV-2 infection in activated CD4+ T cells. This was ex-
pected since SAMHD1 is phosphorylated and inactive in
cycling cells [38-40]. However, the role of Vpx in the in-
fection of unstimulated primary lymphocytes was dra-
matic. When exposed to HIV-2, these cells did not
become productively infected. PHA stimulation, one or
four days following viral exposure, promoted production
of HIV-2 ROD, ROK, TOE and GL-AN WT, associated
with SAMHD1 down-regulation, whereas GL-AN ∆Vpx
did not replicate in this setting. Therefore, Vpx allows
HIV-2 infection of resting CD4+ T cells, where SAMHD1
is active. Interestingly, HIV-1 also replicates in CD4+ T
cells activated after viral exposure [57,58], without degrad-
ing SAMHD1. This may be due to the efficiency of the
HIV-1 reverse transcriptase, which displays a low Kd for
dNTPs, and may thus function in non-cycling cells with a
low dNTP environment [33,34,59,60]. Therefore, both
HIV-1 and HIV-2 infect non-cycling CD4+ T cells [31,36],
through different mechanisms. HIV-2 may require Vpx to
antagonize SAMHD1, in order to increase the intracellular
levels of dNTPs or to avoid degradation of viral nucleic
acids, probably because the reverse transcription process
is less efficient for HIV-2 than for HIV-1 [61].
Discrepant results have been reported in the literature
regarding the interaction of HIV-2 with MDDCs in cell
culture systems [42,44,52]. We show here that MDDCs
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Figure 4 VSV-G pseudotyping allows HIV-2 entry in MDDCs. (a) HIV-2 binding. MDDCs were exposed to the indicated doses of HIV-2 GL-AN,
pseudotyped or not with VSV-G. After 2 h at 4°C, cells were extensively washed and the amount of cell-associated p27 was assessed by ELISA.
Data are Mean ± SD of 4 independent donors. ns: non significant (b) HIV-2 fusion. MDDCs were exposed to the indicated doses of HIV-2 GL-AN,
pseudotyped or not with VSV-G, and bearing the chimeric protein β-lactamase-Vpr. After 2 h at 37°C, viral access to the cytoplasm was assessed
by flow cytometry, using the ability of β -lactamase to cleave the cytoplasmic CCF2-AM fluorogenic substrate. One representative donor is shown
in the upper panel and a mean ± SD of 3 independent donors in the lower panel. *: p-value < 0.05. Comparisons were made between the
condition indicated and the no VSV condition at the same viral inoculum. (c) HIV-2 DNA synthesis. MDDCs were exposed to HIV-2 GL-AN,
pseudotyped or not with VSV-G, in the presence or absence of AZT. After 3 days, the cells were harvested for HIV-2 DNA quantification by qPCR.
Data are mean ± SD of 2 independent donors.
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are poorly susceptible to HIV-2 replication, using either
the primary viral isolates ROK or TOE, the laboratory-
adapted strain ROD, or the molecular clones GL-AN
and ROD-GFP. These results confirm and extend those
of Duvall et al. [52], who showed that primary HIV-2
strains, isolated from either viremic and aviremic pa-
tients, do not detectably infect myeloid DCs. We also
observed that upon exposure with HIV-2, SAMHD1 was
partly down-regulated in MDDCs. This suggests that
Vpx could access the cytoplasm and that viral fusion
could occur to some extent. Future work will help under-
standing why the partial down-regulation of SAMHD1
was not associated with productive HIV-2 infection. Fur-
thermore, we show here that the GL-AN strain, when
pseudotyped with VSV-G, gained the capacity to infect
MDDCs. This process required Vpx, since GL-AN (VSV)
∆Vpx did not infect these cells. Therefore, primary HIV-2
isolates do not potently infect MDDCs. That VSV-G res-
cued infection strongly suggests that an early stage of the
viral cycle is restricted in these cells. We further deter-
mined that viral binding to MDDCs occurred normally
with HIV-2. This is not surprising since HIV binding may
involve multiple receptors and molecules (CD4, lectins
like DC-SIGN and Siglec/CD169, heparan sulfate, etc.…)
and does not necessarily lead to productive infection.
However, viral fusion was severely impaired with viruses
bearing the HIV-2 envelope. Accordingly, viral DNA syn-
thesis did not occur efficiently. Both viral fusion and DNA
synthesis were rescued by VSV-G pseudotyping. It will be
worth determining if sensitivity to restriction factors such
as LV-2 or REAF [26,30,62] are relieved when viral parti-
cles are pseudotyped with VSV-G. Our results also suggest
that the productive infection of MDDCs reported in the
literature [41,42,44] was due to VSV-G pseudotyping, or
to the use of HIV-2 strains with a strong tropism for these
cells. It will also be important to determine whether the
distinct myeloid DC subsets that have been identified [63]
show different susceptibility to HIV-2 replication.
The low susceptibility of MDDCs to infection by HIV-
2 primary isolates was associated with a poor triggering
of an innate immune response. In cells exposed to HIV-2,
we did not observe induction of the interferon-stimulated
Figure 5 HIV-2 ROD-GFP and MDDCs. (a) Susceptibility of MDDCs to HIV-2 ROD-GFP infection. MDDCs were exposed to HIV-2 ROD-GFP,
pseudotyped or not with VSV-G (50 and 150 ng p27 mL-1, respectively). After 3 days, the levels of GFP were measured by flow cytometry. Results from
6 independent donors are shown (b) HIV-2 ROD-GFP binding. MDDCs were exposed to the indicated doses of HIV-2 ROD-GFP, pseudotyped or not
with VSV-G. After 2 h at 4°C, cells were extensively washed and the amount of cell-associated p27 was assessed by ELISA. Data are Mean ± SEM of 4
independent donors. ns: non significant (c) HIV-2 ROD-GFP fusion. MDDCs were exposed to the indicated doses of HIV-2 ROD-GFP, pseudotyped or
not with VSV-G, and bearing the chimeric protein β-lactamase-Vpr. After 2 h at 37°C and 2 h at room temperature, viral access to the cytoplasm was
assessed by flow cytometry, using the ability of β -lactamase to cleave the cytoplasmic CCF2-AM fluorogenic substrate. A mean ± SEM of 4 independent
donors is shown. *: p-value < 0.05. Comparisons were made between the condition indicated and the no VSV condition at the same viral inoculum.
(d) HIV-2 ROD-GFP DNA synthesis. MDDCs were exposed to HIV-2 ROD-GFP pseudotyped or not with VSV-G, in the presence or absence of AZT. After
3 days, the cells were harvested for HIV-2 DNA quantification by qPCR. Data are mean ± SEM of 4 independent donors.
Chauveau et al. Retrovirology  (2015) 12:2 Page 9 of 13
gene MxA. Our results confirm those of Duvall et al., who
did not observe cell maturation or cytokine production by
myeloid DCs exposed to primary HIV-2 isolates or to the
CBL-20 laboratory-adapted virus [52]. In addition, we re-
port that infection with VSV-pseudotyped HIV-2 triggered
MxA expression in MDDCs. It has been recently reported
that the capsids of HIV-2 are determinants for immune
detection of viral cDNA in MDDCs by the sensor cGAS
[42]. These results were obtained with VSV-G-pseudotyped
HIV-2 ROD. Further work will assess how natural HIV-2
isolates can be sensed by cGAS [64] in MDDCs and other
cell types.
Altogether, our results strongly suggest that primary
HIV-2 isolates are not efficiently sensed by MDDCs.
This does not support the hypothesis that HIV-2,
endowed with Vpx, may naturally infect these cells to
trigger a protective immune response. We conclude ra-
ther that HIV-1 and HIV-2 avoid immune detection in
MDDCs through different mechanisms. HIV-1 does not
efficiently infect these cells because of a lack of a Vpx-
like activity, whereas HIV-2 is restricted at an early entry
stage that is not linked to SAMHD1 blockade.
Our findings that MDDCs are not sensitive to HIV-2
infection are in agreement with in vivo observations
[65]. It has been reported that in Macaques, myeloid
cells were not the site of productive SIV infection, irre-
spectively of Vpx. Rather, the viral DNA present in mye-
loid cells of these animals resulted from phagocytosis of
infected T cells [65].
Conclusion
Overall, our results extend previous studies on the inter-
action of HIV-1 and HIV-2 with CD4+ T cells and DCs.
We show that various HIV-2 strains infect activated
CD4+ T cells. HIV-2 also latently infects non-stimulated
CD4+ T cells. The primary HIV-2 strains tested do not
naturally replicate in MDDCs. The main differences be-
tween HIV-1 and HIV-2 regarding their interactions
with CD4+ T cells and MDDCs include: (i) a potentially
lower level of HIV-2 replication in primary activated
CD4+ T cells; (ii) a distinct molecular mechanism to tar-
get non-activated CD4+ T cells (HIV-2 necessitates Vpx,
whereas HIV-1 infection occurs without the need of a
Vpx-like activity); (iii) a low efficiency of HIV-2 infection
in MDDCs despite the presence of Vpx. It is tempting to
speculate that some of these variations may improve our
understanding of why the natural course of HIV-2 infec-
tion in vivo is different from that of HIV-1 [1,2].
Methods
Cells and reagents
PBMCs were isolated from the blood of healthy donors
by Ficoll centrifugation. The blood was provided by the
EFS (Etablissement français du sang, the Official French
blood bank). CD4+ T lymphocytes were isolated from
PBMCs by positive selection using magnetic beads
(Miltenyi Biotech). When stated, CD4+ T cells were acti-
vated by PHA (1 μg mL−1) and grown with IL-2 for
3 days before infection. Primary CD4+ lymphocytes were
grown in RPMI medium with 10% heat-inactivated fetal
bovine serum (FBS). Monocytes were isolated using a
CD14+ selection kit (Miltenyi Biotech). MDDCs were
generated by culturing monocytes with 50 ng mL−1 IL-4
and 10 ng mL−1 GM-CSF for 5 days. The reverse tran-
scriptase inhibitor AZT (25 μM) was from the NIH
AIDS reagents program.
Viruses
The ROK primary HIV-2 was isolated nine years after
initial diagnosis from an aviremic stage C patient with
low CD4 counts (18 and 24 CD4+ T cells/μL at diagno-
sis and sampling time, respectively). The TOE primary
HIV-2 was isolated 3 years after initial diagnosis. During
this period, the patient always presented undetectable
viral load and a high CD4 cell count (404 to 436 CD4+
T cells/μL at diagnosis and sampling time, respectively).
Viruses were isolated by co-cultivation of patient cells
with a pool of PHA-activated PBMCs of healthy donors
[66]. The primary viruses, as well as the prototype ROD
HIV-2 strain isolated from a Cape Verdian patient [67]
were grown either on PHA-stimulated PBMC or in
HUT-78 T cells. The pGL-AN WT and ΔVpx plasmids
(a kind gift from Florence Margottin-Goguet) [50] were
used to produce viruses by transfection of 293 T cells as
described or by amplification on HUT-78 cells. TOE is a
X4-tropic virus, whereas ROD and ROK are dual tropic
viruses [68]. GL-AN carries a large part of the ROD en-
velope and likely displays the same receptor usage as
ROD. ROD-GFP (a kind gift of Oliver Keppler and Oliver
Fackler) is derived from the ROD9 provirus and encodes
GFP in Nef [36]. Vesicular Stomatitis Virus type G (VSV-
G) pseudotyped viruses GL-AN WT and GL-AN ∆Vpx
were generated by cotransfection of 293 T cells with the
corresponding proviruses and a VSV-G expression plas-
mid. The SIV3+ WT and the ∆Vpx plasmids (a kind gift
from Monsef Benkirane) were used to produce VLP as de-
scribed [32,69].
HIV-2 infection
Primary CD4+ T cells were exposed to the indicated virus
(15 to 90 ng mL−1 of p27) for 3 h at 37°C in the presence
of 2 μg mL−1 of DEAE-Dextran (Sigma-Aldrich). The in-
fection was then monitored by flow cytometry analysis
after intracellular Gag staining (KC-57 mAb, Coulter) or
by p27 ELISA (Zeptometrix) on the culture supernatants.
For infection of non-activated CD4+ T cells, the virus was
extensively washed after 4 h at 37°C. Half of the cells were
activated with PHA (PHA16, Oxoid, 1 μg mL−1) at day 1
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or 4 post infection. The other half was kept in the pres-
ence of low concentration of IL-2 (10 U mL−1). The infec-
tion was then followed by flow cytometry at the indicated
days.
MDDCs were seeded in flat-bottomed 96-well plates
at 1×105 cells per well. Cell-free infections in MDDCs
were performed using indicated viral doses (50 ng mL−1
of p27 for the VSV-G pseudotyped viruses and 150 to
500 ng mL−1 of p27 for the non-pseudotyped viruses).
AZT was added 2 h before infection and kept through-
out the infection.
Flow cytometry
For Gag and SAMHD1 staining, cells were fixed with
PFA 4% for 10 min followed by permeabilization with
PBS-Triton 0.5% for 20 min. Cells were stained either
with the mouse monoclonal antibody (mAb) anti-
SAMHD1 (clone I19-18) coupled with Alexa 488 [35] or
with a rabbit polyclonal anti-SAMHD1 (Proteintech,
12586-1-AP) for 30 min at 4°C. We previously reported
that the levels of SAMHD1 detected by flow cytometry
correlated with western blot analysis [35]. Gag stainings
were performed with the KC57 mAb (Beckman and
Coulter) or with anti-capsid mAb clones 183-H12-5C
(NIH AIDS Reagent Program) and 25-26A (Hybridolab,
Institut Pasteur). MxA staining was performed with
MN143 mAb (provided by Otto Haller) in PBS-Saponine
0.05% for 30 min at 4°C [70]. Samples were analyzed
with a FACS CANTO II (Becton Dickinson).
HIV-2 binding assay
HIV-2 GL-AN and ROD-GFP pseudotyped or not with
the VSV-G envelope (50 and 150 ng mL−1 of p27) were
used to infect 3 × 105 MDDCs in 300 μL at 4°C, in pres-
ence of 10 mM Hepes. After 2 h, cells were extensively
washed in PBS. Two third of the cells were resuspended
in 200 μL PBS + 20 μL Lysis Buffer from the SIV p27
ELISA kit (Zeptometrix). The amount of cell-associated
p27 was measured by ELISA.
HIV-2 fusion assay
Viral fusion was assessed as described [54,55]. Briefly,
ultracentrifuged HIV-2 virions containing the Blam-
Vpr2 fusion protein (a gift of Matthias Dittmar, [55])
were used to infect 1.5 × 105 MDDCs in 100 μL at 37°C,
in presence of 10 mM Hepes and 2 mg.mL-1 DEAE
Dextran (Sigma). After 2 hours, cells were washed in
cold CO2-independent medium (Invitrogen), without
FBS, resuspended in cold CO2-independent medium
supplemented with 10% FBS and incubated with the
CCF2-AM substrate (CCF2-AM kit, Invitrogen), in the
presence of 1.8 mM Probenecid (Sigma), for 2 hours at
room temperature. Cells were extensively washed in cold
CO2-independent medium and fixed in PBS-PFA 4% for
5 min. The cleaved CCF2-AM fluorescence (excitation
at 405 nm, emission at 450 nm) was then immediately
measured by flow cytometry using the DAPI channel, on
a FacsCanto II (BD).
HIV-2 DNA quantification
Infected cells DNA was extracted using the DNeasy
Blood and Tissue kit (Qiagen). 50 ng of total DNA were
used with the Platinum qPCR SuperMix-UDG (Life
Technologies) and amplified on an Eppendorf Mastercy-
cler ep realplex2 apparatus. HIV-2 Gag primers and probe,
as well as PCR conditions have been described [71].
Statistical analysis
Statistic analysis was performed with the Mann–Whitney
test.
Additional file
Additional file 1: Figure S1. Flow cytometry analysis of CD4+ T cells
and MDDCs. a. Staining of resting and activated CD4+ T cells. Unstimulated
CD4+ T cells and PHA-activated cells (day 3 post activation) were stained for
CD69 and Ki67 (activation and proliferation markers, respectively) and
analysed by flow cytometry. The FSC/SSC gatings are depicted. The isotype
control is in grey. One representative donor is shown. b. MxA staining of
MDDCs. MDDCs were exposed to HIV-2 GL-AN WT (VSV) (50 ng p27 mL-1),
with or without AZT, as described in Figure 3. After 3 days, the levels of MxA
were measured by flow cytometry. One representative experiment is
depicted. c. HIV-2 Gag levels in MDDCs at day 4 post infection. MDDCs were
exposed to HIV-2 ROD, GL-AN (150 ng p27 mL-1) and GL-AN WT (VSV) and
GL-AN ∆Vpx (VSV) (50 ng p27 mL-1). After 4 days, the levels of Gag and
SAMHD1 were measured by flow cytometry. Data are Mean of 2 independent
donors.
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